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Axonal target-derived BMPand neurotrophin signaling are both known to regulate neuronal gene expression,
differentiation, and axon growth. In this issue of Neuron, Ji and Jaffrey (2012) discovered that BMP-signaling
endosomes depend on BDNF-induced axonal synthesis of SMADs to retrogradely regulate transcription
in developing trigeminal neurons, providing a mechanism of integrating the two target-derived signals.During nervous system development,
axonal target-derived signals can induce
transcriptional changes which are essen-
tial for neuronal differentiation and correct
assembly of neural circuits. The rodent
trigeminal sensory system has served
as an excellent model to study such
processes. Cutaneous sensory informa-
tion from three distinct facial regions is
transmitted to the brain by the three
branches of the trigeminal ganglion:
ophthalmic (Op), maxillary (Mx), and
mandibular (Md) branches (Figure 1A). A
number of facial target-derived signals
have been shown to regulate different
aspects of the specification, peripheral
axon growth, central axon projection,
and survival of developing trigeminal
sensory neurons (Davies, 1997; O’Connor
and Tessier-Lavigne, 1999; Hodge et al.,
2007; da Silva et al., 2011). Two factors
in particular, brain-derived neurotrophicfactor (BDNF) and bone morphogenic
protein 4 (BMP4), have been the focus of
recent study, including a paper in this
issue of Neuron from Ji and Jaffrey
(2012). In early embryonic development,
between embryonic days E10 and E12,
BDNF is expressed by both the
ophthalmic and maxillary targets as well
as the corresponding pathway mesen-
chyme, and it serves as one of the ‘‘che-
moattractants’’ that attract the axon
outgrowth of trigeminal peripheral axons
(Figure 1A; O’Connor and Tessier-
Lavigne, 1999). After initial axon exten-
sion, BMP4, which is also selectively
expressed by epidermis in the ophthalmic
and maxillary regions at these stages,
retrogradely signals to trigeminal neurons
and induces spatially patterned expres-
sions of several transcription factors
along the dorsoventral axis of the trigem-
inal ganglion (Hodge et al., 2007). Onesuch BMP4-retrograde signaling induced
gene is Tbx3 (Figure 1A).
The intracellular mechanisms that
mediate this BMP4-retrograde signal in
trigeminal neurons have been unclear. Ji
and Jaffrey (2012) describe an interesting
union between BDNF-induced axonal
translation of SMADs (which are effectors
carrying out the BMP transcriptional
signaling) and axon-derived BMP4-sig-
naling endosomes that together mediate
the retrograde specification of trigeminal
neurons (summarized in Figure 1B).
Using microfluidic chambers for com-
partmentalized cultures and separate
manipulations of trigeminal neuron cell
bodies versus axons, the authors estab-
lished that adding BMP4 to the axons
resulted in the appearance of phos-
phorylated-SMAD1/5/8 (pSMADs) within
15 min and Tbx3 gene transcription within
4 hr in the neuronal cell bodies. To showon 74, April 12, 2012 ª2012 Elsevier Inc. 3
Figure 1. Target- and Pathway-Derived BDNF through TrkB Signaling Stimulates the
Translation of SMAD1/5/8 in the Axons and Growth Cones of TG Sensory Neurons in the Op
and Mx but Not the Md Branches
Op and Mx target-derived BMP4 binds BMP receptors and induces the formation of retrograde signaling
endosomes in TG neurons. The BMP signaling endosomes require axonally synthesized SMADs to elicit
transcriptional changes such as induction of Tbx3 gene.
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Previewsthat BMP4 retrograde signaling endo-
somes were required for this process,
they applied biotinylated-BMP4 to the
axons and subsequently found the endo-
cytosed BMP4 within cell bodies. Both
the retrograde transport of BMP4 and
the downstream signaling (as assayed
by pSMADs and Tbx3) were blocked by
a dynein (the retrograde motor protein)
inhibitor. Furthermore, adding BMP-
receptor kinase inhibitors selectively to
the cell body compartment prevented
retrograde signaling by BMP4 applied to
the axons. This result suggested that
activated BMP-receptors, presumably
those residing on the axon-derived
endosomes with internalized BMP4, are
required at the neuronal cell bodies for
eliciting downstream signal transduction
(Figure 1B, growth cone and cell body
panel).
The authors next sought to identify the
sources of SMADs. Previous studies
have shown that phosphorylated SMAD
proteins are present in trigeminal axons
contacting BMP4-expressing targets
(Hodge et al., 2007). Ji and Jaffrey (2012)
also showed that their mRNAs could be
localized in axons both in culture and
in vivo (Figure 1B, middle panel), leading
to the question of whether the axonal
SMAD proteins were derived from intra-
axonal translations of the corresponding
mRNAs. Several lines of evidence indi-4 Neuron 74, April 12, 2012 ª2012 Elsevier Incated that this was indeed the case.
Protein synthesis blockers applied to the
axon chamber resulted in the depletion
of SMAD proteins in axons, as the axonal
SMADs were constitutively transported
back to cell bodies by a dynein-based
mechanism (Figure 1B, middle panel).
When a Dendra2-SMAD1 (with 30UTR
of Smad1) construct was expressed
in cultured trigeminal neurons, photo-
conversion of Dendra2-SMAD1 fusion
protein located at the cell bodies showed
that photo-converted proteins did not
diffuse into axons; thus, there was
minimum anterograde transport of
SMADs to the axons. Further, the authors
showed that when the axons were
severed from their cell bodies and then
photo-bleached, the fluorescence recov-
ered within 10 min, which could only
occur if the new fluorescent protein was
synthesized locally within the cut axons.
Ji and Jaffrey (2012) went on to show
that BMP retrograde signaling required
axonally synthesized SMADs. Either
blocking axonal protein synthesis with
inhibitors or applying a siRNA cocktail
against SMAD1/5/8 selectively to axon
chambers diminished retrograde induc-
tion of Tbx3 and pSMADs in cell bodies
by BMP4. Howmight the axonal synthesis
of SMADs proteins be regulated? The
authors noticed that in vivo, SMADs
proteins were present in the ophthalmicc.and maxillary but not the mandibular
branches of trigeminal nerves, despite
the fact that SMADs mRNAs were
observed in all branches. BDNF was
previously known to be highly expressed
along the pathways and in the targets of
the ophthalmic and maxillary branches,
but not of the mandibular branch
(Figure 1A; O’Connor and Tessier-
Lavigne, 1999). A clue to the how the
BDNF data may relate to regulation of
SMAD protein expression came from the
observation that BDNF itself could be
used to induce SMADs protein translation
in isolated axons in culture and that
this effect was local, not requiring retro-
grade Trk signaling (Figure 1B, right
panel). Likewise, in BDNF null mutant
embryos, which were known to have
normal initial axon outgrowth at stages
E10–E11.5 (O’Connor and Tessier-
Lavigne, 1999), there were significantly
reduced axonal SMADs, decreased
nuclear pSMADs, and diminished Tbx3
expression in trigeminal sensory neurons
of theOp andMxdivisions. These findings
provided in vivo evidence that target-
derived BDNF is critical for the translation
of SMADs in axons and for BMP4-retro-
grade signaling in developing trigeminal
neurons. It is also worth noting that the
authors performed multiple control ex-
periments, including those that showed
protein synthesis inhibitors, Trk-kinase
inhibitor, as well as siRNA applied to
axons did not affect axonal transport.
The interesting findings presented in
this paper also raise several questions.
Why would axonal translation of SMAD
proteins be needed in the first place
when there are SMADs produced at the
cell body? The BMP-signaling endo-
somes are retrogradely transported back
to the cell body, so shouldn’t the recep-
tors on the endosomes be able to phos-
phorylate the cell body derived SMADs
and induce downstream transcriptional
changes just as well? One possible expla-
nation offered by the authors is that
perhaps activated receptors are more
efficient at recruiting SMADs located in
the vicinity during endocytosis through
adaptor proteins (Moustakas and Heldin,
2009), although this idea was not tested.
On the other hand, it is not inconceivable
that axons synthesize more SMAD
proteins than is possible in the cell bodies.
Considering that the diameter of an
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Previewsembryonic trigeminal sensory neuron is
about 10 mm with a large nucleus of
89 mm in diameter, this makes the net
cytoplasm of the cell body roughly
1,600 mm3. At E11.5, the trigeminal axons
have grown roughly 1,000 mm in length,
and with a diameter of 1 mm, the volume
of the axonal cytoplasm is about
3,000 mm3. The growth cones vary in
size, but many are larger than the cell
body. Thus, together, the total volume of
cytoplasm in axon and growth cone can
be significantly larger than that of cell
body, potentially containing more mate-
rials for protein synthesis. Although the
number of ribosomes in axons is fewer
than that in cell bodies, at the same
time, only selected mRNAs species are
located in axons. It is also possible that
the axonal ribosomes may be dedicated
to translate only select proteins and
could therefore potentially synthesize
more of particular SMADs than does
the cell body. The anti-SMAD immunoflu-
orescence staining results in this and
previous studies (Ji and Jaffrey, 2012;
Hodge et al., 2007) showed that the axons
of trigeminal neurons in the ophthalmic
and maxillary branches showed strong
signal (and hence high concentrations of
SMADs) all along the axon. These axonal
SMADs are constantly and rapidly trans-
ported back to cell bodies. Depleting
this major source of SMAD synthesis
could thus severely reduce the total
amount of SMADs, thereby hindering
BMP signaling.
Another related question is if SMADs
are phosphorylated within the axons and
are trafficked back to cell bodies, why is
there a need for BMP-signaling endo-
somes to be present in cell bodies.
Perhaps pSMADs are labile and there
are many negative regulatory mecha-
nisms at the cell body that could lead to
either rapid degradation or inactivation
of pSMADs (Moustakas and Heldin,
2009), and thus a persistent source of
activated BMP receptors is needed for
sustaining the retrograde signaling. As to
the BDNF-induced axonal translation of
SMAD mRNAs, it would be interesting to
examine whether the induction mecha-nism in trigeminal axons is similar to
what has been shown for BDNF-induced
translation in dendrites/synapses, which
occurs primarily through activating the
mTOR pathway to modulate translation
initiation and elongation (Santos et al.,
2010).
There are also some outstanding
general questions. For example, how are
mRNAs and ribosomes transported into
axons? It is generally believed that
mRNAs are delivered to dendrites and
axons in ‘‘granules’’ (Kiebler and Bassell,
2006). Large granules may contain ribo-
some subunits (Sossin and DesGroseil-
lers, 2006). However, it is unclear whether
all mRNAs are transported by granules.
Studies in nonneuronal cells have found
that a large populations of mRNAs en-
coding cytosolic (nonsecretory, non-
membrane) proteins are localized to the
endoplasmic reticulum (ER) (Pyhtila
et al., 2008). In other words, there are
signal-sequence-independent mecha-
nisms that direct mRNA localizations to
the ER. Since the ER permeates the entire
neuron including the axonal processes,
some mRNAs could be simply carried by
the ER into axons (Figure 1B).
Accumulating evidence has shown that
axons of nonmammalian neurons and
embryonic mammalian neurons have
the capacity to synthesize proteins, and
in vivo in the adult mouse, ribosomes
could be transferred from Schwann cells
to the injured distal axons of the periph-
eral nerve (Twiss and Fainzilber, 2009,
and the references therein). Nevertheless,
ribosomes were rarely observed in axons
ofmature central nervous system neurons
in mammals, although they could be
found in the axon hillock (Steward,
1997). The cellular mechanisms that
prevent ribosomes from entering into the
axons of mature neurons remain unclear,
although it is conceivable that in immature
growing neurons, ribosomes may move
into axons as part of the vectorial flow
of cytoplasm (Bradke and Dotti, 1997).
Perhaps as the neurons mature and
become polarized, their axon initial
segment (AIS) is established and the AIS
serves as a selective cytoplasmic ‘‘filter’’Neur(Song et al., 2009) that excludes ribo-
somes from getting into axons. This
possibility could, in principle, be exam-
ined in mature neurons in which the AIS
is acutely disrupted by conditional dele-
tion of the specific ankyrin G isoform
(Grubb and Burrone, 2010).
Finally, it will also be interesting to
examine whether this mechanism of inte-
grating two major types of target-derived
signals, i.e., neurotrophic factors stimu-
lating the axonal synthesis of SMADs
and TGFb-superfamily factors forming
retrograde signaling endosomes, is used
elsewhere in the nervous system for
retrograde specification of neuronal sub-
type identities.
REFERENCES
Bradke, F., and Dotti, C.G. (1997). Neuron 19,
1175–1186.
da Silva, S., Hasegawa, H., Scott, A., Zhou, X.,
Wagner, A.K., Han, B.X., and Wang, F. (2011).
Proc. Natl. Acad. Sci. USA 108, 3395–3400.
Davies, A.M. (1997). J. Anat. 191, 483–491.
Grubb, M.S., and Burrone, J. (2010). Curr. Opin.
Neurobiol. 20, 481–488.
Hodge, L.K., Klassen,M.P., Han, B.X., Yiu, G., Hur-
rell, J., Howell, A., Rousseau, G., Lemaigre, F.,
Tessier-Lavigne, M., and Wang, F. (2007). Neuron
55, 572–586.
Ji, S.-J., and Jaffrey, S.-R. (2012). Neuron 74, this
issue, 95–107.
Kiebler, M.A., and Bassell, G.J. (2006). Neuron 51,
685–690.
Moustakas, A., and Heldin, C.H. (2009). Develop-
ment 136, 3699–3714.
O’Connor, R., and Tessier-Lavigne, M. (1999).
Neuron 24, 165–178.
Pyhtila, B., Zheng, T., Lager, P.J., Keene, J.D.,
Reedy, M.C., and Nicchitta, C.V. (2008). RNA 14,
445–453.
Santos, A.R., Comprido, D., and Duarte, C.B.
(2010). Prog. Neurobiol. 92, 505–516.
Song, A.H., Wang, D., Chen, G., Li, Y., Luo, J.,
Duan, S., and Poo, M.M. (2009). Cell 136, 1148–
1160.
Sossin, W.S., and DesGroseillers, L. (2006). Traffic
7, 1581–1589.
Steward, O. (1997). Neuron 18, 9–12.
Twiss, J.L., and Fainzilber, M. (2009). Trends Cell
Biol. 19, 236–243.on 74, April 12, 2012 ª2012 Elsevier Inc. 5
